Location: Dublin, Ireland
Looking for The CRISPR Forum 2018?
CO-CHAIRS: Professor Eric Hendrickson (University of Minnesota Medical School) and Dr Jon Moore (Horizon Discovery)
The discovery of the RNA programmable nucleases Cas9 and Cpf1 has revolutionized a researcher's ability to interrogate and understand genes. The impact of CRISPR genome editing technology has been universal and unescapable, bringing drug discovery to an era of whole genome knockout screens and development of translational in vitro and in vivo models of disease, as well as moving into the clinic, progressing towards transformative gene-based therapies for human diseases.
This unique meeting was held in Dublin on 17-18 October and brought together leaders in the field together with a wide academic and commercial audience, to explore the new horizons in drug development and therapeutics brought by advancements in CRISPR technology.
What made this meeting different:
A substantial proportion of the oral programme was given to talks selected from submitted abstracts to discuss innovative ideas
There was a focus on closing the gap between new developments in CRISPR technology and application in life sciences
This event was held in association with The Pathologist, media partner to The CRISPR Forum 2017.
The CRISPR Forum 2017 was also sponsored by GEN - Genetic Engineering & Biotechnology News.
Join The CRISPR Journal Community and find out about this new publication, launching 2018.
Tuesday 17 October
CRISPR-Cas9 as a new chapter in the history of gene editing (13:00-13:45)
13:00 - Eric Hendrickson (Minnesota) - Mechanism of gene editing
Therapeutic applications of CRISPR-Cas9 (13:45-14:50)
13:45 - Linda Popplewell (RHU) - Towards therapy of Duchenne Muscular Dystrophy
14:10 - Patrick Harrison (Cork) - Homology Independent Targeted Integration to correct multiple Cystic Fibrosis mutations
14:35 - Speaker TBC
Improvements in CRISPR Technology (15:20-17:10)
15:20 - Anna Cersesoto (University of Trento) - From user to genome-friendly CRISPR-Cas9
15:45 - Marcello Maresca (AstraZeneca) - In vivo base editing and genome editing for target validation and disease modelling
16:00 - Thomas Machleidt (Promega) - CRISPR-mediated tagging of endogenous proteins with a luminescent peptide
16:15 - Nadia Hegarat (University of Sussex) - Development of new chemical genetics approaches in human cell lines based on CRISPR mediated gene
16:40 - TBA (Labcyte)
17:00 - Ben Kleinstiver (Massachusetts General Hospital) - Improving the specificity and versatility of CRISPR nucleases
Attendee dinner in evening
Wednesday 18 October
Target ID & validation A (09:00-10:40)
09:00 - Carlos le Sage (Horizon) - Compare and contrast CRISPR KO, CRISPRi and CRISPRa
09:25 - Jon Moore (Horizon) - Synthetic lethal target ID
09:50 - Melissa Kelley (Dharmacon) - TBC
10:15 - Paul Datlinger (Austrian Academy of Sciences) - CROP-seq: pooled CRISPR screens with single cell transcriptome readout
Target ID & validation B (11:10-12:45)
11:10 - Shanade Dunn (Sanger Inst) - CRISPR-Cas9 screening to identify novel combination targets for PI3K pathway inhibitors in breast cancer
11:25 - Yaron Galanty (University of Cambridge) - TBA, Whole genome CRISPR screens
11:50 - Colm Ryan (University College Dublin) - Cancer GD: a bioinformatics tool
12:05 - Tilmann Buerkstuemmer (Horizon) - Using CRISPR for rapid generation of conditional mutants
12:30 - Jonathan Wrigley (AstraZeneca) - Precise genome editing: generating CRISPR models of disease and drug resistance
Lunch & Networking
Applications (14:15 – 16:20)
14:15 - Andrew Bassett (Sanger Inst) - Using CRISPR to understand miRNA target site regulation
14:40 - Kilian Huber (SGC, Oxford) - Target ID via proteomics and CRISPR/Cas9
15:05 - Zhi Liu (System Biology Ireland, UCD) - Functional analysis of the MAPK scaffold KSR1 in malignant melanoma
15:20 - Srinivas Suda (Natn. Inst. Cell. Biotech, Dublin) - Engineering miRNA to enhance CHO cell performance in biopharma productivity
15:35 - Sarah Stewart (University of Cambridge) - A genome-wide CRISPR screen reconciles the role of N-linked glycosylation in galectin-3 transport to the cell surface
15:50 - Michael D’Angelo (University of Cambridge) - CRISPR/Cas9 genome edited models of STAT3 activated lysosome mediated cell death in mammary epithelial cells.
Closing remarks (16:05-16:20)
16:05 - Jon Moore - Closing remarks
CALL FOR PRESENTATIONS
Areas of particular interest included:
CRISPR Drug Discovery and development
If you are involved in arranging similar educational meetings and conferences, and looking for support, please do let us know by emailing email@example.com
Find out more about Horizon CRISPR Screening